Physician profile
Wesley Forgue
NPI 1649229360
$1,570.50
in general payments reported to CMS, 2019-2025
11 companies · $63.52 in 2025
The $63.52 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $548 · 2020: $200 · 2021: $141 · 2022: $336 · 2023: $39.32 · 2024: $242 · 2025: $63.52.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $341 · Education: $3.82.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $341.47 |
| Education | $3.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius USA Marketing, INC. | $425.32 | 2019-2025 | Velphoro, Velphoro |
| Amgen INC. | $363.59 | 2019-2024 | Tavneos |
| Mallinckrodt Enterprises LLC | $217.07 | 2019 | |
| Ani Pharmaceuticals, INC. | $165.30 | 2024-2025 | Purified Cortrophin Gel |
| Mallinckrodt Hospital Products INC. | $147.69 | 2020 | |
| Akebia Therapeutics INC | $134.57 | 2019-2025 | Vafseo |
| Astrazeneca Pharmaceuticals Lp | $49.60 | 2020-2021 | |
| Vifor Pharma, INC. | $25.64 | 2023 | Korsuva, Veltassa |
| Otsuka America Pharmaceutical, INC. | $23.72 | 2019 | |
| Ardelyx, INC. | $14.18 | 2024 | Ibsrela |
| Travere Therapeutics, INC. | $3.82 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wesley Forgue listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.